- Oct 10, 2024 Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
- Oct 01, 2024 Foghorn Therapeutics to Participate in the BMO Oncology Summit
- Sep 03, 2024 Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
- Aug 28, 2024 Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
- Aug 08, 2024 Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
- May 28, 2024 Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
- May 22, 2024 Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
- May 20, 2024 Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
- May 06, 2024 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
- Apr 16, 2024 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Displaying 31 - 40 of 119